𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma

✍ Scribed by Ying Waeckerle-Men; Edith Uetz-von Allmen; Markus Fopp; Roger von Moos; Christel Böhme; Hans-Peter Schmid; Daniel Ackermann; Thomas Cerny; Burkhard Ludewig; Marcus Groettrup; Silke Gillessen

Publisher
Springer-Verlag
Year
2006
Tongue
English
Weight
518 KB
Volume
55
Category
Article
ISSN
0340-7004

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

High dose dexamethasone and base of brai
High dose dexamethasone and base of brain irradiation for hormone refractory metastatic carcinoma of the prostate
✍ K. Hellmann; R. H. Phillips; M. Goold 📂 Article 📅 1993 🏛 Springer 🌐 English ⚖ 242 KB

High dose dexamethasone combined with irradiation to the base of the brain achieved a dramatic beneficial effect in two terminal cases of widespread metastatic carcinoma of the prostate involving cranial nerves and the entire skeleton. Pain requiring very large doses of analgesics and anemia requiri

Molecular mechanisms for apigenin-induce
Molecular mechanisms for apigenin-induced cell-cycle arrest and apoptosis of hormone refractory human prostate carcinoma DU145 cells
✍ Sanjeev Shukla; Sanjay Gupta 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 415 KB

## Abstract Development of effective agents for treatment of hormone‐refractory prostate cancer has become a national medical priority. We have reported recently that apigenin (4′,5,7‐trihydroxyflavone), found in many common fruits and vegetables, has shown remarkable effects in inhibiting cell gro

Thromboembolic events with estramustine
Thromboembolic events with estramustine phosphate-based chemotherapy in patients with hormone-refractory prostate carcinoma : Results of a meta-analysis
✍ Gregory M. Lubiniecki; Jesse A. Berlin; Rachel B. Weinstein; David J. Vaughn 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB 👁 1 views

## Abstract ## BACKGROUND Combinations of cytotoxic chemotherapy with estramustine phosphate (EMP), a nornitrogen mustard‐estrogen conjugate, are used to treat patients with hormone‐refractory prostate carcinoma (HRPC). However, thromboembolic events (TE), including deep venous thrombosis (DVT), p

Infusion of dendritic cells pulsed with
Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease
✍ Murphy, G.P.; Tjoa, B.A.; Simmons, S.J.; Jarisch, J.; Bowes, V.A.; Ragde, H.; Ro 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 225 KB 👁 2 views

## Background: A phase ii trial was conducted to assess the efficacy of infusions of dendritic cells (dc) and two hla-a2-specific psma peptides (psm-p1 and -p2). this report describes thirty three subjects with hormone-refractory metastatic prostate cancer without prior vaccine therapy history who